Oxford Nanopore Prevails in Patent Ruling against Pacific Biosciences
Today the European Patent Office revoked Pacific Biosciences patent EP3045542 with claims to a single molecule sequencing process wherein two strands of DNA are linked by a connecting nucleic acid. The validity of the patent had been challenged by Oxford Nanopore.
The EPO ruled that the claims to a single molecule sequencing process were unsupported in the application and that the application only supported a template-directed synthesis sequencing method. As Pacific Biosciences were unwilling to accept this change, the patent was revoked.
The decision by the EPO is consistent with a recent decision by the International Trade Commission (ITC) to limit the claims of a related Pacific Biosciences US patent to template-directed synthesis.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LR-HEALTH-&-BEAUTY15.10.2019 17:25:30 CEST | Press release
The success story of the Aloe Vera Drinking Gel by LR Health & Beauty continues
RCRC15.10.2019 16:51:08 CEST | Press release
International Experts Invited to Attend Riyadh’s Sustainable City Symposium
MUNDIPHARMA15.10.2019 16:07:07 CEST | Press release
Mundipharma presents wealth of data for Penthrox®▼ (methoxyflurane) at EUSEM Congress, demonstrating superiority compared to standard of care in trauma pain in adults
BITEPRO15.10.2019 16:02:07 CEST | Press release
British Firm BitePRO Claim Education Professionals Are Bitten By Pupils On Daily Basis
NY-MSCI15.10.2019 15:13:05 CEST | Press release
MSCI Schedules Investor Conference Call to Review Third Quarter 2019 Results
CLIENTRON-CORP.15.10.2019 15:02:04 CEST | Press release
Clientron Unveils Its Brand New AiO Thin Client TC238 With Intel® Smart Display Module (Intel® SDM) for Optimized Display Computing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom